# of Displayed Technologies: 19 / 19

Applied Category Filter (Click To Remove): Vaccines


Categories

Combination B Cell Epitope Vaccines for Cancer Treatment
TS-064843 — , T2022-244, T2020-109 : Cancer vaccines targeting a combination of B Cell epitopes to improve patient outcomes.
The Need Despite the clinical success of checkpoint receptor blockade in various cancer subtypes, many patients develop resistance, presenting a pressing need for novel approaches. Current inhibitors, like PD-1/PD-L1 and HER-2 exhibit limited efficacy and significant toxicities, underscoring the d…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Preventative Human T-cell leukemia virus type 1 vaccine
TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…
  • College: College of Veterinary Medicine
  • Inventors: Panfil, Amanda; Green, Patrick; Niewiesk, Stefan
  • Licensing Officer: Dahlman, Jason "Jay"

A novel VSV-based vaccine platform for Zika virus
TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…
  • College: College of Medicine (COM)
  • Inventors: Peeples, Mark; Li, Jianrong
  • Licensing Officer: Dahlman, Jason "Jay"

Live Attenuated Mumps Virus-Based SARS-CoV-2 Vaccines for Infants and Children
TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Boyaka, Prosper; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

Novel method for attenuating live vaccine candidates for non-segmented negative-sense RNA viruses
TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; He, Chuan; Lu, Mijia; Niewiesk, Stefan; Peeples, Mark; Xue, Miaoge; Zhang, Zijie; Zhao, Boxuan
  • Licensing Officer: Dahlman, Jason "Jay"

A Novel Vaccine for Listeriosis Infection
TS-049471 — Listeriosis is an infectious disease caused by the bacterial pathogen Listeria monocytogenes. Although the average number of cases is moderate in the United States (1600-2500/year), listeriosis is a significant health concern due to its exceptionally high fatality rate. Indeed, listeriosis is the …
  • College: OSU Wexner Medical Center
  • Inventors: Seveau, Stephanie
  • Licensing Officer: He, Panqing

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: He, Panqing

Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
  • College: College of Engineering (COE)
  • Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
  • Licensing Officer: He, Panqing

Novel Immunomodulators and Vaccine Adjuvants
TS-038032 — A class of compounds possessing potent immunomodulatory activity, to enhance the protection of vaccines against infectious agents.
While vaccines are commonly used today for a variety of diseases and have proven efficacious for disease prevention, some vaccines do not efficiently activate an immune response. About 10% of vaccinations fail to mount adequate antibody levels to routine vaccinations. Also, many viruses rapidly mu…
  • College: College of Medicine (COM)
  • Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Fuchs, James; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

Novel Live Attenuated Vaccines for Pneumoviruses
TS-037753 — A method to create vaccines for pneumoviruses, using recombinant viruses.
The Need Pneumoviruses consist of pathogens that target the upper respiratory tract within their specific hosts. These include many important human and animal pathogens, such as human respiratory syncytial virus (hRSV), hMPV, bovine RSV, pneumonia virus of mice (PVM), and avian metapneumovirus (aMP…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Cai, Hui; Peeples, Mark; Wang, Rongzhang
  • Licensing Officer: Dahlman, Jason "Jay"

Novel Live Attenuated Vaccines for Human Metapneumovirus
TS-037675 — Novel method of using live attenuated vaccines to prevent infection of hMVP.
The Need: Human metapneumovirus (hMPV) is a prevalent pathogen causing acute respiratory tract disease in individuals of all ages, especially infants, children, the elderly, and immunocompromised individuals. Despite its global prevalence, there are currently no therapeutics or vaccines available fo…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Li, Jianrong; Wei, Yongwei; Zhang, Yu
  • Licensing Officer: Dahlman, Jason "Jay"

A Novel Vectored Vaccine Against Human Norovirus
TS-037664 — A live recombinant vesicular stomatitis virus (VSV)-vector vaccine composition for human norovirus.
The Need Human norovirus (HuNoV) is a highly contagious and prevalent pathogen responsible for the majority of foodborne gastroenteritis outbreaks worldwide. As HuNoV cannot be grown in cell cultures, developing an effective vaccine against it has proven challenging. Current vaccine studies using v…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Li, Jianrong; Ma, Yuanmei
  • Licensing Officer: Dahlman, Jason "Jay"

Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
The Need: Respiratory Syncytial Virus (RSV) is a major cause of infant hospitalization due to acute lower respiratory tract infections (ALRI) in children under 5 years of age globally, causing up to 200,000 deaths annually. RSV leads to significantly more hospitalizations than influenza in children …
  • College: College of Veterinary Medicine
  • Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
  • Licensing Officer: Dahlman, Jason "Jay"

Improved Mucosal Immune Response During Vaccination
TS-015239 — Enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.
The Need: Enhancing Mucosal Immune Response for Effective Vaccination Infectious agents primarily invade the body through mucosal tissues, necessitating a robust immune response at these vulnerable sites. However, conventional vaccines often fail to induce sufficient immunoglobulin-A (IgA) antibodi…
  • College: College of Veterinary Medicine
  • Inventors: Boyaka, Prosper
  • Licensing Officer: Dahlman, Jason "Jay"

Mutant Hydrogenase Bacteria for Use against Enteric Pathogens
TS-015013 — Hydrogenase enzyme deficient bacterial strains that may be used as vaccines or attenuating agents for enteropathogenic diseases.
Enteric pathogens are responsible for an estimated two million deaths annually and cause millions more cases of diarrheal illness even in developed countries. When an individual contracts an enteric pathogen such as S. typhimurium, the infected individual will continue to shed the pathogen for up …
  • College: College of Medicine (COM)
  • Inventors: Gunn, John
  • Licensing Officer: Taysavang, Panya

Loading icon